【摘要】 目的 對(duì)市場(chǎng)上流通使用的血塞通注射液在溶血性方面的狀況進(jìn)行考察與研究?！》椒ā“础吨袊幍洹?005年版一部附錄ⅩⅧ B中藥注射劑安全性檢查法應(yīng)用指導(dǎo)原則和中藥、天然藥物刺激性和溶血性研究的技術(shù)指導(dǎo)原則，對(duì)11 個(gè)廠家共計(jì)27 批血塞通注射液每批次樣品制備4 個(gè)濃度，進(jìn)行溶血實(shí)驗(yàn)研究，并采用分光光度法（545 λ/nm）測(cè)定計(jì)算溶血率，比較各批次樣品的溶血率。 結(jié)果 不同廠家甚至同一廠家不同批次的血塞通注射液溶血率存在一定差異。 結(jié)論 在臨床使用中應(yīng)注意用量，過量使用可能導(dǎo)致溶血引起的不良反應(yīng)；同時(shí)，應(yīng)注意溶血引起的臨床不良反應(yīng)的觀測(cè)。【Abstract】 Objective To explore the hemolysis of Xuesaitong injection. Methods According to the Guiding Principles of safety tests on traditional Chinese medicine injection in Annex ⅩⅧ B, Chinese Pharmacopoeia, 2005 Edition 1, and Technical Guidelines of studies on the irritability and hemolytic activity of traditional Chinese medicine and natural medicine, a total of 27 samples of Xuesaitong injections (each sample was diluted into four concentrations) produced by 11 manufacturers had been examined. Spectrophotometry (545 λ/nm) was used to calculate the hemolytic rate. Results There was a certain difference in the hemolytic rate among several samples of Xuesaitong injections produced by different manufacturers, or even different batches by the same manufacturer. Conclusion The dosage of Xuesaitong injections should be noted in clinical use. Excessive use may lead to adverse reactions caused by hemolysis; at the same time, clinical adverse reactions caused by hemolysis should be observed.
目的探討內(nèi)皮素（ET）在梗阻性黃疸肝、腎、心組織損傷中的作用機(jī)理及血塞通注射液的保護(hù)作用。方法健康日本大耳白兔72只，雌雄各半，采用完全隨機(jī)分組方法隨機(jī)均分為3組: 膽總管結(jié)扎（BDL）組、BDL+血塞通注射液組及假手術(shù)組。建立實(shí)驗(yàn)動(dòng)物模型，分別于術(shù)后3、6、9及21 d取材。用全自動(dòng)生化分析儀測(cè)定各組動(dòng)物血清總膽紅素、谷丙轉(zhuǎn)氨酶、尿素氮及肌酐； 用放免法測(cè)定各組動(dòng)物肝、腎、心組織及血漿中的ET水平。結(jié)果BDL組和BDL+血塞通注射液組與假手術(shù)組比較，動(dòng)物血漿及肝、腎、心組織中的ET含量明顯升高（P＜0.01)，肝、腎功能損害更嚴(yán)重(P＜0.01); BDL+血塞通注射液組比BDL組血漿及組織中ET含量明顯降低(P＜0.05)，肝、腎功能損害亦減輕（P＜0.05）。結(jié)論梗阻性黃疸可導(dǎo)致血漿及肝、腎、心組織ET含量升高,且隨梗阻時(shí)間延長(zhǎng)升高愈明顯； 血塞通注射液通過降低血漿及組織的ET水平，發(fā)揮對(duì)梗阻性黃疸肝、腎、心損害的保護(hù)作用。